(KRNY) Announces Stock Offering Results and Expected Closing Date

(BAGR) to Acquire Eighteen Buffalo Wild Wings Restaurants

$54 Million Accretive Transaction Expected to Close in July

Conference Call to Discuss Acquisition Scheduled for 5:00 PM EDT Today

SOUTHFIELD, Mich., May 14, 2015  — Diversified Restaurant Holdings, Inc. (Nasdaq:BAGR) (“DRH” or the “Company”), the creator, developer and operator of the unique, full-service, ultra-casual restaurant and bar Bagger Dave’s Burger Tavern® (“Bagger Dave’s”) and one of the largest franchisees for Buffalo Wild Wings® (“BWW”), announced today its intention to acquire eighteen Buffalo Wild Wings restaurants in the St. Louis area for $54 million. Buffalo Wild Wings Inc. has already provided the waiver of its Right of First Refusal. The acquisition will allow DRH to own the entire St. Louis market and also provide for the opportunity to open new BWW stores.

Subject to customary closing conditions, the accretive transaction is expected to close in July and is conditioned upon availability of financing. DRH has engaged Citizens Bank, its senior lender, to lead a bank syndicate in order to finance 100% of the transaction with a senior-secured debt facility. DRH is confident that the facility will close and the resulting leverage and coverage ratios will remain comfortably within the Company’s covenant limits. The Company intends to update its annual guidance upon the closing of the transaction.

Michael Ansley, President and CEO of DRH, commented, “We are delighted to be acquiring 18 highly-successful and very profitable BWW restaurants in the St. Louis area. We expect they will be immediately accretive to earnings, reinforce our already strong leadership position in the BWW system, and allow us to expand into a new market with opportunities for future growth and in close proximity to our core geography. Throughout our history, we have proven our ability to leverage our ‘best practices’ expertise, G&A infrastructure and systems to drive higher unit volumes and stronger profitability at acquired BWW restaurants in Indiana, Illinois and Florida. We are therefore highly confident that we can apply our know-how to this transaction as well, and in doing so, enhance shareholder value.”

Conference Call

DRH will host a conference call with an accompanying slide presentation to discuss the acquisition today at 5:00 PM Eastern Daylight Time. The conference call can be accessed live by dialing 1-877-407-3982 or 1-201-493-6780 for international callers. A replay will be available two hours after the end of the call and can be accessed by dialing 1-877-870-5176 or 1-858-384-5517 for international callers; the conference ID is 13610145. The replay will be available until midnight on May 21, 2015.

The live and later archived webcast can be accessed through the Company’s website at www.diversifiedrestaurantholdings.com.

Upcoming Investment Conference

DRH will present at the Stephens Spring Investment Conference on Tuesday, June 2, 2015 at The New York Palace Hotel. The presentation will begin at 4:00 PM Eastern Daylight Time. Additionally, DRH will be participating in one-on-one meetings with investors at the conference. Interested investors should contact the conference organizers at Stephens Inc.

About Diversified Restaurant Holdings

Diversified Restaurant Holdings, Inc. (Nasdaq:BAGR) (“DRH” or the “Company”) owns and operates Bagger Dave’s Burger Tavern, a full-service, family-friendly restaurant and full bar with a casual, comfortable atmosphere specializing in custom-built, proprietary, fresh prime rib recipe burgers, all-natural turkey burgers, hand-cut fries, locally crafted beers on draft, hand-dipped milk shakes, salads, black bean turkey chili, and much more. There are currently 26 company-owned Bagger Dave’s restaurants in Michigan and Indiana. For more information, visit www.baggerdaves.com.

The Company also operates 42 Buffalo Wild Wings Grill & Bar franchised restaurants in Indiana, Illinois, Michigan, and Florida.

The Company routinely posts news and other important information on its website at www.diversifiedrestaurantholdings.com.

Safe Harbor Statement

The information made available in this news release contains forward-looking statements which reflect DRH’s current view of future events, results of operations, cash flows, performance, business prospects and opportunities. Wherever used, the words “anticipate,” “believe,” “expect,” “intend,” “plan,” “project,” “will continue,” “will likely result,” “may,” and similar expressions identify forward-looking statements as such term is defined in the Securities Exchange Act of 1934. Any such forward-looking statements are subject to risks and uncertainties and the Company’s actual growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities could differ materially from historical results or current expectations. Some of these risks include, without limitation, the impact of economic and industry conditions, competition, food and drug safety issues, store expansion and remodeling, labor relations issues, costs of providing employee benefits, regulatory matters, legal and administrative proceedings, information technology, security, severe weather, natural disasters, accounting matters, other risk factors relating to our business or industry and other risks detailed from time to time in the Securities and Exchange Commission filings of DRH. Forward-looking statements contained herein speak only as of the date made and, thus, DRH undertakes no obligation to update or publicly announce the revision of any of the forward-looking statements contained herein to reflect new information, future events, developments or changed circumstances or for any other reason.

CONTACT: For more information contact:

         Investor Relations Contact:
         Raphael Gross
         ICR Inc.
         203.682.8253
         raphael.gross@icrinc.com

(CYRN) Dell Email Security to Include CYREN Cybersecurity Antimalware Technology

MCLEAN, Va., May 14, 2015  — CYREN (NASDAQ: CYRN) today announced an agreement with Dell that adds CYREN’s antimalware technology to Dell SonicWALL Email Security appliances, software, virtual appliances and hosted services.

With the additional layer of protection offered through the CYREN antimalware solution, Dell further strengthens its position as one of the most secure, sophisticated and widely deployed email security solutions available today.

Featuring consistently top-rated detection capabilities, CYREN maximizes protection while minimizing the load on the host platform. Designed to efficiently detect malware and advanced threats, CYREN uses a multi-layered approach through heuristics, emulation, and cloud-driven logic, fed continuously by the intelligence of the CYREN Cloud, within a modular framework that can quickly address fast-evolving threats. It serves as an integral layer of security for Dell’s email security products prioritizing performance while maintaining maximum protection.

CYREN’s antimalware technology is powered by CYREN’s Cyber Intelligence Platform that analyzes billions of Internet transactions each day, providing real-time intelligence while aggregating a wide range of threats from email, web and IP traffic.

“By adding CYREN’s engine to our Dell SonicWALL email security solutions, we’re creating a powerful multi-engine approach to security that further boosts protection for our clients,” said Edward Cohen, executive director of strategy and business development for Dell Software. “CYREN proved to be easily integrated into our platform and offers a level of performance that is vital for our users.”

“We are pleased that CYREN can provide a crucial layer of antivirus security for Dell SonicWALL’s email security products,” said Lior Samuelson, CEO and Chairman of the Board at CYREN. “Speed and efficiency are always the highest priorities for companies looking to integrate a primary or multi-level approach to malware protection. CYREN is well known for providing both. Offering a highly-valued combination of simple integration, maximum performance and top-notch detection capabilities, CYREN stands as the ultimate security partner.”

For more information on Dell SonicWALL email security products, visit:
www.sonicwall.com/us/en/products/email-security.html

About CYREN
Founded in 1991, CYREN (NASDAQ and TASE: CYRN) is a long-time innovator in cyber intelligence, powering the security solutions of more than 200 of the largest IT and security technology providers in the world. As the security provider to the security industry, CYREN maintains the broadest and deepest real-time Internet threat database in the world. Every day, CYREN collects and analyzes 17 billion pieces of threat data to protect 600 million global users. Threat data is gathered and cyber intelligence disseminated through 500,000 global points of presence in 200 countries.  Visit www.cyren.com.

Blog: blog.cyren.com
Facebook: www.facebook.com/CyrenWeb
LinkedIn: www.linkedin.com/company/cyren
Twitter: twitter.com/CyrenInc

© 2015 CYREN Ltd. CYREN and GlobalView are trademarks of CYREN Ltd. Other company and product names may be trademarks of their respective owners.

U.S. Investor Contact:
Garth Russell
KCSA
212.896.1250
grussell@kcsa.com

Israel Investor Relations Contact:
Iris Lubitch
SmarTeam
+972.54.2528007
iris@smartteam.co.il

CYREN Company Contact:
Mike Myshrall, CFO
CYREN
703.760.3320
mike.myshrall@cyren.com

CYREN Media Contact:
Matthew Zintel
Zintel Public Relations
281.444.1590
matthew.zintel@zintelpr.com

(ATOS) Sponsors 8th Annual Walk with Love Fundraiser

(NETE) Schedules Conference Call & Releases Q1 FY2015 Financials

(NURO) Announces First Shipments of Quell™ Wearable Pain Relief Device

NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has started shipping Quell wearable pain relief devices out of its production and fulfillment facility in Woburn, MA. The initial shipments are directed to leading doctors and thought leaders in chronic pain. The Company anticipates that it will start fulfilling orders in late May that were placed through its pre-order campaign on the Indiegogo platform. The Company expects to clear the remaining backorders and begin ongoing commercial shipments for new orders in June. The Company has an order backlog of about 2000 Quell devices.

Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide pain relief. The device is designed for people with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia, and pain associated with osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device have the option of using their smartphone to automatically track and personalize their pain therapy through the Quell Relief app, an updated version of which was released this week in the Apple app store.

“Initiating shipments of Quell represents a significant milestone for NeuroMetrix. This is an important step in completing our transformation from a traditional medical device company to one focused on the growing consumer healthcare market,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “Our employees have worked very hard to achieve this goal, and we are justifiably proud of this important achievement. We now look forward to growing Quell into a large and successful consumer healthcare brand.”

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements that involve a number of known and unknown risks, uncertainties and other factors that may cause such forward-looking statements not to be realized. We believe these factors include but are not limited to those described under “Risk Factors” in our Annual Report on Form 10-K, as such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our Annual Report on Form 10-K and other filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit www.QuellRelief.com and www.NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

(HCKT) “IT Must Focus on Four Imperatives”

To achieve world-class performance in the digital era, IT organizations must focus on four imperatives, according to new IT Key Issues Research from The Hackett Group (NASDAQ:HCKT): translate technology innovation into business innovation opportunities; manage and mitigate the impact of complexity; redesign the IT service delivery model to support business technology convergence; and support the company’s information transformation journey.

“The best IT leaders are realizing that the way they’ve operated in the past no longer cuts it,” said IT Executive Advisory Practice Leader Scott Holland. “The traditional mindset of building systems that are robust, predictable, and to spec isn’t enough anymore. Yes, you need to keep the legacy systems running. But greater agility and flexibility is required, and IT needs to be able to turn on a dime to support the changing needs of the business and create real strategic advantage.”

The Hackett Group’s research found that for the enterprise, high levels of volatility and uncertainty persist, driving a combined focus on agility and innovation. An IT focus on agility and speed is key, as IT often has a critical impact on time-to-market, with technology development efforts integral to product or services launches. Companies are also concerned with an array of risks, led by intensified competition, access to critical talent, and regulatory risk. Many of these risks have impact on IT.

At the same time, IT budgets and staffing are both expected to see only modest increases in 2015, according to The Hackett Group’s research, with staff increasing by 3.3 percent and budgets by 3.1 percent. These increases are significantly higher than those seen in last year’s study. But cost pressures continue, and IT investments are being made strategically, in key areas, including data and analytics, mobile, and cloud-based initiatives.

The need to support a technology-led enterprise innovation agenda and enable enterprise agility is related to the transition from the industrial to the digital era, The Hackett Group’s research finds. This translates into four world-class IT imperatives.

Translate Technology Innovation into Business Innovation – Innovation is a core component of virtually all business growth strategies, and digital business transformation is on the agenda of the majority of companies. At the same time, technology innovation is progressing at a relentless pace, manifested in technologies such as cloud computing, big data analytics, the Internet of Things, mobile apps, and social media. IT’s ability to translate this technology innovation into business innovation opportunities is rapidly becoming a core attribute of world-class IT performance, the research finds. This is a complex, multifaceted issue involving business partnering capability maturity, technology innovation competency, innovation process integration, and the maturity and business savvy of technology talent, along with enterprise innovation culture.

Learn to Live with Technology Complexity – Widespread frustration about IT’s inability to keep up with business demands is in part a result of complexity in technology infrastructures that has been created in recent decades. As a result, most resources in many IT organizations are now consumed by just running these systems. Ability to focus on value-added activities, including innovation, is predicated on how well complexity in the traditional technology environment is managed, the research finds. Aspiring to actually reduce technology complexity in the digital age is not realistic. Instead, it must be minimized and managed. In addition, the need to manage the deluge of data generated in the digital era will introduce additional complexity into the technology environment.

Reinvent the IT Service Delivery Model – IT organizations also need to fundamentally change their service delivery model to stay relevant as the lines between what was traditionally defined as either “the business” or “IT” continue to blur, The Hackett Group recommends. Technology is rapidly becoming pervasive and integral to all aspects of the core business, changing the way the IT organization engages with it. As the distinction between IT and the business gradually becomes less relevant, the issue of how IT engages with the business evolves into governance issues about how technology decisions are made. With the explosion of on-demand, cloud-based technologies, sourcing models are also undergoing a complete overhaul. Most importantly, IT needs to develop or bring in new talent to stay relevant in the digital age.

Plan and Execute the Information Transformation Journey – Of all the emerging technologies, analytics has perhaps the greatest potential for business value creation, the research finds. But to truly optimize the use of big data requires comprehensive transformation that goes beyond incremental change. Mobility and cloud-based analytics are further accelerating the value of analytics, but at the same time creating additional technology selection, security, and application development challenges for IT organizations. For many companies, a commitment to analytics and big data coincides with changes in the decision-making culture and in the nature of value creation from product-centric to information- and service-centric. IT organizations are being challenged to redefine their role in this transition.

The Hackett Group’s new study, “IT Key Issues in 2015: Innovation and Agility are Driving the IT Agenda,” is based on results gathered from executives from over 170 large companies in the US and abroad, most with annual revenue of $1 billion or greater. A complimentary version of the research is available with registration at this link: http://www.thehackettgroup.com/research/2015/pr/keyissuesit15/

About The Hackett Group

The Hackett Group (NASDAQ: HCKT) is an intellectual property-based strategic consultancy recognized as the leading enterprise benchmarking and best practices implementation firm to Global 2000 companies. Services include business transformation, enterprise performance management, working capital management, and global business services. The Hackett Group also provides dedicated expertise in business strategy, operations, finance, human capital management, strategic sourcing, procurement, and information technology, including its award-winning Oracle EPM and SAP practices.

The Hackett Group has completed more than 11,000 benchmarking studies with major corporations and government agencies, including 93% of the Dow Jones Industrials, 86% of the Fortune 100, 87% of the DAX 30 and 51% of the FTSE 100. These studies drive its Best Practice Intelligence Center™ which includes the firm’s benchmarking metrics, best practices repository, and best practice configuration guides and process flows, which enable The Hackett Group’s clients and partners to achieve world-class performance.

More information on The Hackett Group is available at: www.thehackettgroup.com, info@thehackettgroup.com, or by calling (770) 225-3600.

(RENT) Cross-Platform Entertainment Rankings – May 13, 2015

–Only Rentrak Precisely Measures Movies & TV Everywhere–

PORTLAND, Ore., May 13, 2015  — Rentrak (NASDAQ: RENT), the leader in precisely measuring movies and TV everywhere, today announced the top weekly cross-platform entertainment rankings for May 13, 2015.

Disney/Marvel’s “Avengers: Age of Ultron” continues to dominate the global movie marketplace, holding strong as the number one movie in many markets and boasting another impressive $68.3 million weekend internationally. It came in ahead of China’s opening this week and has a massive global total to-date of $875.3 million. Additionally, Universal reports “Pitch Perfect 2” is off and running with a solid $8.8 million, including number one debuts in Australia and New Zealand this weekend in advance of its North American debut later this week.

In North America, “Ultron” makes it two weekends in a row at the top of the chart, posting the second highest second weekend gross ($77.7 million), surpassing the second weekend of Fox’s “Avatar” ($75.6 million), and is topped only by “Marvel’s The Avengers” ($103.1 million).  Impressively, the movie ties the second place ten-day industry record as the fastest movie to reach the $300 million plateau (ties WB’s “The Dark Knight,” topped only by the nine-day all-time record held by “Marvel’s The Avengers”).

On our digital purchases and rentals chart, Warner Bros.’ “American Sniper” debuts very strong in its first week of release taking the number one spot. Notably, “Sniper” set a January weekend record in theaters earlier this year. Paramount’s “Interstellar,” now in its sixth week of release, continues to impress, descending slightly to third. Fox’s “Cake,” starring Jennifer Aniston in one of her more dramatic roles for which she was nominated for a Golden Globe for Best Actress – Motion Picture Drama, also had a strong opening week, coming in at number five.

Both our Movies on Demand chart and our DVD & Blu-ray Disc rentals chart is led by Sony’s Kevin Hart comedy “The Wedding Ringer” this week, while on the sales side of the DVD and Blu-ray ledger, the well-reviewed and much-loved “Paddington” from Anchor Bay took the top spot and thus found its way home for keeps with enthusiastic families and their kids.

Telemundo’s “El Senor de los Cielos” and “Duenos del paraiso” top our broadcast TV engagement chart this week with CBS’s “Blue Bloods” coming in third place. Meanwhile, VH1’s “Love and Hip Hop Atlanta” leads the charge on our cable TV engagement chart with Bravo’s “The Real Housewives of Atlanta” taking second and WeTV’s “Mary Mary” in third.

On our combined social media and digital engagement chart for viewers of broadcast and cable telecasts, NBC’s “The Voice” regained the top spot this week with only the top 10 contestants remaining. In second, Spike TV’s “Lip Sync Battle” continued another successful week of battles with the help of Terry Crews and Mike Tyson. In third place, ABC’s long-running “Grey’s Anatomy” shocked its fan base with the death of a main character.

Click the links below to view the most recent charts:

Worldwide Box Office
Domestic Box Office
DVD & Blu-ray Disc Sales
DVD & Blu-ray Disc Rentals
Movies on Demand
Digital Movies Sales & Rentals
TV & Social Media Engagement

About Rentrak Corporation
Rentrak (NASDAQ: RENT) is the entertainment and marketing industries’ premier provider of worldwide consumer viewership information, precisely measuring actual viewing behavior of movies and TV everywhere. Using our proprietary intelligence and technology, combined with advanced demographics, only Rentrak is the census currency for VOD and movies. Rentrak provides the stable and robust audience measurement services that movie, television and advertising professionals across the globe have come to rely on to better deliver their business goals and more precisely target advertising across numerous platforms including box office, multiscreen television and home video. For more information on Rentrak, please visit Rentrak.com.

RENTM

Contacts:
Paul Dergarabedian
Senior Media Analyst
Office: 818.917.9697
Email: pauld@rentrak.com

Antoine Ibrahim
PR Specialist
Office: 646.722.1561
Email: aibrahim@rentrak.com

(DSCO) to Announce Results from AEROSURF® Phase 2a Clinical Trial

Conference Call Scheduled for Thursday, May 14, 2015 at 8:00 a.m. Eastern Time

WARRINGTON, Pa., May 13, 2015  — Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will announce top-line results from its AEROSURF^® Phase 2a clinical trial in premature infants 29 – 34 gestational age with respiratory distress syndrome (RDS) on Thursday, May 14, 2015 at approximately 7:00 a.m. EDT.

Discovery Labs management will host a conference call and live webcast, including a slide presentation, on Thursday, May 14, 2015 at 8:00 a.m. EDT to review and discuss the results of the trial. The live webcast and archive of the conference call can be accessed at http://discoverylabs.investorroom.com/events.

For “listen-only” participants and those who wish to take part in the question and answer portion of the call, dial (888) 346-0767 (domestic) or (412) 902-4251 (international). After placing the call, request to be joined into the Discovery Labs conference call.  A replay of the conference call will be accessible one hour after completion through May 22, 2015 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference ID number 10065912.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases.  Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival.  If surfactant deficiency or degradation occurs, the air sacs in the lungs can collapse, resulting in severe respiratory diseases and disorders.  Discovery Labs’ technology platform includes a novel synthetic peptide-containing (KL4) surfactant, that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant.  Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of aerosolized surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

For more information, please visit the Company’s website at www.Discoverylabs.com.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties are described in Discovery Labs’ filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.

(GIGA) Receives $3.0 Million Order for High Performance YIG Tuned Filter Products

SAN RAMON, Calif., May 13, 2015  — Giga-tronics Incorporated (Nasdaq:GIGA) announced today that it has received a $3.0 million order extending ongoing production of its high performance YIG filters for a major aerospace company. The Company expects to start shipments for this order in September 2015. The order will be fulfilled by Giga-tronics’ Microsource subsidiary co-located with the Company’s instrument division in San Ramon, California. John Regazzi, President and CEO of Giga-tronics, said “We are pleased to have our customer’s continued confidence in Giga-tronics to deliver this sole sourced product on time, while meeting their high standards for quality and reliability.”

Giga-tronics is a publicly held company, traded on the NASDAQ Capital Market under the symbol “GIGA”.  Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.

This press release contains forward-looking statements concerning operating results, future orders, sales of new products, long term growth, shipments, and customer acceptance of new products. Actual results may differ significantly due to risks and uncertainties, such as: delays in customer orders for the new Advanced Signal Generation System, receipt or timing of future orders, cancellations or deferrals, our ability to continue as a going concern, our need for additional financing, possible delisting from trading on the NASDAQ Capital Market and moving to the OTCQB marketplace; the volatility in the market price of our common stock; and general market conditions.  For further discussion, see Giga-tronics’ most recent annual report on Form 10-K for the fiscal year ended March 29, 2014, Part I, under the heading “Risk Factors” and Part II, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Results of Operations”.

CONTACT: Steven D. Lance
         Vice President of Finance/Chief Financial Officer
         slance@gigatronics.com
         (925) 302-1056

(OHGI)’s China Aishuo App Surpasses 3 Million Downloads

(GTIM) Announces Opening of New Good Times Restaurant in Aurora, Colorado

Good Times Restaurants Inc. (Nasdaq: GTIM), operator of Good Times Burgers & Frozen Custard, a regional quick service restaurant chain focused on fresh, high quality, all natural products and of Bad Daddy’s Burger Bar, a full service, upscale concept today announced that it opened a new Good Times Burgers & Frozen Custard at the Shops at Arapahoe Commons in Aurora, Colorado on May 7, 2015. The Company also reported it closed on a sale leaseback transaction for the site on April 30, 2015.

“We built a new freestanding prototype designed restaurant that incorporates the same design features that we implemented in a second generation site last fall that includes more upscale finishes such as whitewashed barnwood, stained concrete floors, industrial metals and lighting and natural woods with design features that reflect Good Times’ brand position around taking a better food stand,” said Boyd Hoback, President and CEO. “We will look at our footprint and continue to optimize the size of the restaurant, number of seats and overall curb appeal as we look to build more Good Times in Colorado and position the brand for growth outside of Colorado.”

Regarding the sale leaseback transaction, Hoback added, “We were also able to access the 1031 exchange market with multiple offers on the site that resulted in what is for us a record low rental cap rate of 5.85% and a very attractive rent structure on the store.”

About Good Times Restaurants Inc.

Good Times Restaurants Inc. (GTIM) operates Good Times Burgers & Frozen Custard, a regional chain of quick service restaurants located primarily in Colorado, in its wholly owned subsidiary, Good Times Drive Thru Inc. Good Times provides a menu of high quality all natural hamburgers, 100% all natural chicken tenderloins, fresh frozen custard, fresh cut fries, fresh lemonades and other unique offerings. Good Times currently operates and franchises 38 restaurants.

GTIM also operates Bad Daddy’s Burger Bar restaurants, of which there are 13 company owned and franchised restaurants currently operating. Bad Daddy’s Burger Bar is a full service, upscale, “small box” restaurant concept featuring a chef driven menu of gourmet signature burgers, chopped salads, appetizers and sandwiches with a full bar and a focus on a selection of craft microbrew beers in a high energy atmosphere that appeals to a broad consumer base. Bad Daddy’s was founded in Charlotte, North Carolina.

Good Times Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. The words “intend,” “may,” “believe,” “will,” “should,” “anticipate,” “expect,” “seek” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, which may cause the Company’s actual results to differ materially from results expressed or implied by the forward-looking statements. These risks include such factors as the uncertain nature of current restaurant development plans and the ability to implement those plans, delays in developing and opening new restaurants because of weather, local permitting or other reasons, increased competition, cost increases or shortages in raw food products, and other matters discussed under the “Risk Factors” section of Good Times’ Annual Report on Form 10-K for the fiscal year ended September 30, 2013 filed with the SEC. Although Good Times may from time to time voluntarily update its forward-looking statements, it disclaims any commitment to do so except as required by securities laws.

(FCSC) Receives Rare Pediatric Disease Designation From FDA for FCX-007

Gene-Therapy Drug Candidate is Potential First-in-Class Treatment for RDEB — A Rare, Congenital, Devastating Skin Disease

EXTON, Pa., May 12, 2015  — Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell’s lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.

“We are pleased that the FDA has granted our request to designate FCX-007 for the treatment of RDEB as a drug for a rare pediatric disease,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell. “FCX-007 may offer RDEB patients and their families the first therapy to treat the underlying cause of the disease, bringing hope and relief to what is today a painful, disabling and often fatal congenital disorder.

“We are also pleased that the incentives offered by both the Orphan Drug and rare pediatric disease designations—including the potential to obtain a valuable Rare Pediatric Disease Priority Review Voucher from the FDA—could provide additional ways to create value for our shareholders.”

About Rare Pediatric Disease Designation

The FDA defines a “rare pediatric disease” as a disease that affects fewer than 200,000 individuals in the U.S. primarily aged from birth to 18 years. Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying new drug application (NDA) or biologics license application (BLA) for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a Rare Pediatric Disease Priority Review Voucher that can be used to obtain priority review for a subsequent NDA or BLA. The Priority Review Voucher may be sold or transferred an unlimited number of times.

About FCX-007

FCX-007 is Fibrocell’s novel gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a congenital and progressive orphan skin disease caused by the deficiency of the protein type VII collagen (COL7).  FCX-007 is a gene-modified autologous fibroblast that encodes COL7 and is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. By genetically modifying autologous fibroblasts to produce COL7, ex-vivo, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas, avoiding systemic treatment. The drug is currently in late stage pre-clinical development with an IND filing targeted for mid-2015.

About Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Recessive dystrophic epidermolysis bullosa (RDEB) is the most severe form of dystrophic epidermolysis bullosa (DEB), a congenital, progressive, devastatingly painful and debilitating genetic disorder that leads to death. RDEB is caused by a mutation of the COL7A1 gene, the gene which encodes for type VII collagen, a protein that forms anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching. Children who inherit the condition are often called “butterfly children” because their skin is as fragile as a butterfly’s wings. There are approximately 1,100 – 2,500 RDEB patients in the U.S.  Currently, there is no cure for RDEB and treatments address only the sequelae, including daily bandaging, hydrogel dressings, antibiotics, feeding tubes and surgeries.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.  Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy.  In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts.  The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).  Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocellscience.com.

Forward-Looking Statements

This press release contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our development strategy, timing and potential advantages of our product candidates.

These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell’s control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; and (ii) whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption “Item 1A. Risk Factors” in Fibrocell’s most recent Form 10-K filing.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell’s most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell’s most recent annual report.

CONTACT: Investor Relations Contact:
         Karen Casey
         Fibrocell Science, Inc.
         405 Eagleview Boulevard
         Exton, PA 19341
         (484) 713-6133
         kcasey@fibrocellscience.com

(CRTN) Tier 1 International Communications Operator Expands Multi-Year Contract With Cartesian

Increases Estimated Contract Revenue by 240% to $34 Million

OVERLAND PARK, Kan., May 12, 2015  — Cartesian™ (Nasdaq:CRTN), a specialist provider of consulting services and managed solutions to the global communications, technology and digital media industries, today announced that it has been awarded an expansion of its 2014 three-year services agreement with an international Tier 1 communications operator, increasing the potential contract revenue by nearly 2.4 times the original value.

Cartesian is helping the Tier 1 operator deliver a number of major transformation programs as the operator expands its investment in the communications infrastructure of one of its major national markets. Based on projected program requirements and including the minimum contract commitment, total contract revenue is forecasted to run up to approximately $34 million, with approximately $28 million coming in 2015 and 2016.

The operator has a long-standing partnership with Cartesian, built on collaboration on a number of previous technology-based initiatives aimed at improving service delivery to the operator’s customer base.

Don Klumb, Cartesian’s CEO, said, “We are thrilled to grow our role in delivering exciting technology and transformation programs that advance and expand services for our client’s customers. This contract builds upon a strong established partnership, and we look forward to continuing to support their key strategic initiatives.”

About Cartesian, Inc.

Cartesian, Inc. (Nasdaq:CRTN) is a specialist provider of consulting services and managed solutions to leaders in the global communications, technology and digital media industries. Cartesian provides consulting in strategy, execution and managed solutions to clients worldwide. The company has offices in Boston, Kansas City, London, New York and Washington.

The Cartesian logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=23353

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, any statements that do not relate to historical or current facts constitute forward-looking statements, including any statements contained herein regarding expectations with respect to the Company’s future business, financial condition and results of operations. Forward-looking statements are subject to known and unknown risks, uncertainties, and contingencies, many of which are beyond the Company’s control, which may cause actual results, performance, or achievements to differ materially from those projected or implied in such forward-looking statements. Factors that might affect actual results, performance, or achievements include the risks described in its periodic reports filed with the SEC, including, but not limited to, “Cautionary Statement Regarding Forward Looking Information” under Part I of its Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and subsequent periodic reports containing updated disclosures of such risks. These filings are available at the SEC’s web site at www.sec.gov. Any forward-looking statements made in this release speak only as of the date of this release. Cartesian does not intend to update these forward-looking statements and undertakes no duty to any person to provide any such update under any circumstances.

CONTACT: Brainerd Communicators, Inc.
         Ray Yeung (Media)
         yeung@braincomm.com

         Corey Kinger (Investors)
         kinger@braincomm.com
         212.986.6667

(PTIE) Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY

REMOXY Meets Both Primary Endpoints with Statistical Significance (p<0.0001)

AUSTIN, Texas, May 12, 2015  — Pain Therapeutics, Inc., (Nasdaq:PTIE) today announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p<0.0001) that both intact and chewed REMOXY were less “liked” than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.

“We believe today’s results demonstrate abuse-deterrent properties of the REMOXY formulation against a common, and often lethal, form of oral drug abuse,” said Nadav Friedmann, PhD, MD., Pain Therapeutics’ Chief Medical Officer.

Study Design

Pain Therapeutics’ former corporate partner for REMOXY had sole responsibility for this FDA Category 3 Human Abuse Potential Study with REMOXY. This study was conducted in accordance with draft FDA Guidance to Industry on Abuse Deterrent Opioids and interactions between the study sponsor and FDA. The study was randomized, double-blind, placebo and active controlled, using a 4-way crossover design in healthy, non-dependent recreational opioid users. Nearly 60 subjects completed this study, with an average age of 27 years. The study’s primary objective was to measure the abuse potential of chewed and intact 40mg REMOXY compared to 40mg immediate-release (IR) oxycodone when taken orally. Study subjects were instructed to chew REMOXY capsules vigorously for up to 5 minutes, but none were able to do so in light of REMOXY’s high viscosity, texture or taste. Pharmacodynamic measures of the primary endpoints, Drug Liking and Drug High, included use of a standard 0-100 point Visual Analogue Scale (VAS) in the initial two hours post-dose (AUC_02h), as recommended by FDA to assess a formulation’s abuse potential. The sponsor generated study tables for this Abuse Potential Study in December 2014. Pain Therapeutics has not performed an independent analysis of study results.

Top-line Study Results

Clinical and statistical highlights include:

• On the co-primary endpoint of Drug Liking, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.
• On the co-primary endpoint of Drug High, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.
• On the secondary endpoint of Good Drug Effects, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.
• On the secondary endpoint of Bad Drug Effects, scores were significantly higher for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0079) compared to IR oxycodone.
• On the secondary endpoint of Pupil Constriction, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0001) compared to IR oxycodone.
• On the secondary endpoint of Nausea, scores were significantly lower for intact REMOXY (p<0.0001) and for chewed REMOXY (p<0.0143) compared to IR oxycodone.
• On the secondary endpoint of Feel Sick, scores were significantly lower for intact REMOXY (p<0.0002) and for chewed REMOXY (p<0.039) compared to IR oxycodone.

“We believe results of today’s study speak to the clinical and commercial potential of REMOXY,” said Remi Barbier, President & CEO of Pain Therapeutics. “REMOXY’s high viscosity is intended to deter injection and snorting. We believe this feature, coupled to today’s data on oral abuse, contributes to an overall assessment of abuse potential that supports a label-claim for REMOXY.”

CONFERENCE CALL

Pain Therapeutics will host a conference call today, Tuesday, May 12^th at 4:30 pm Eastern Time to discuss progress across its portfolio of drug candidates and to respond to questions.

To participate in the conference call, please dial 1-877-407-4018 prior to the start of the call. Those interested in listening to the conference call live via the internet may do so by visiting the Company’s website at www.paintrials.com.

A playback of the call will be available for about 7 days after the live event. To access the playback, please dial 1-877-870-5176 (or international toll-free number 1-858-384-5517) and enter code 1360-9974.

About REMOXY^®

We own world-wide commercial rights to our lead drug candidate, REMOXY Extended-Release Capsules CII, which is a unique, twice-a-day formulation of oral oxycodone. REMOXY’s intended indication is for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time and for which alternative treatments are inadequate. We specifically developed REMOXY to discourage certain common methods of drug tampering and misuse.   The REMOXY NDA is supported by multiple clinical trials, including a successful Phase III efficacy program conducted under a Special Protocol Assessment.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not approved our drug candidates for commercial sale.  For more information, please visit www.paintrials.com.

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding potential resubmission of an NDA for REMOXY with the U.S. Food and Drug Administration, or FDA; the sufficiency of data and other information to support the resubmission and approval of an NDA for REMOXY and support for a label claim for abuse deterrence; the scope of target markets for REMOXY; and statements regarding the benefits of REMOXY.   Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, difficulties or delays in development, testing, regulatory approval, production and marketing of our drug candidates, including REMOXY; unexpected difficulties or delays in the submission and regulatory review of an NDA for REMOXY; unexpected adverse side-effects or inadequate therapeutic efficacy of our drug candidates and other factors that could slow or prevent, development, product approval or market acceptance (including the risk that current and past results of clinical trials and studies may be found to be insufficient for marketing approval); developments of products or technologies by current or future competitors, and the development of competing or alternative therapies.   For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.

CONTACT: Peter S. Roddy
         Vice President and Chief Financial Officer
         Pain Therapeutics, Inc.
         proddy@paintrials.com
         512-501-2450

(MTSL) Announces $500,000 Private Equity Financing

RA’ANANA, Israel, May 11, 2015  —

MTS – Mer Telemanagement Solutions Ltd. (Nasdaq Capital Market: MTSL), a provider of video advertising solutions for online and mobile platforms as well as innovative products and services for telecom expense management, mobile virtual network operators and enablers and an IOT/M2M enablement platform used by mobile service providers, today announced that it had completed a private placement of 227,271 ordinary shares, constituting approximately 2.9% of the Company’s outstanding shares, for $500,000. The proceeds of the placement will be used to augment the Company’s financial position after the acquisition of Vexigo Ltd. and to provide it with additional working capital. The shares were sold to Mr. Lior Salansky, chief executive officer of the Company, and to two directors, Mr. Chaim Mer, Chairman of the Company, and Mr. Adi Orzel, Chairman of the newly acquired Vexigo subsidiary. The price paid per share of $2.20 was equal to the closing price of an ordinary share on the NASDAQ Capital Market on Friday, May 8, 2015. The private equity financing was unanimously approved by the Company’s audit committee and board of directors.

About MTS

Mer Telemanagement Solutions Ltd. (MTS) is a provider of video advertising solutions for online and mobile platforms as well as innovative products and services for telecom expense management (TEM), enterprise mobility management (EMM), mobile virtual network operators and enablers (MVNO/MVNE), billing mobile money services and solutions and an IOT/M2M enablement platform used by mobile service providers.

Headquartered in Israel, MTS markets its solutions through wholly owned subsidiaries in Israel, the United States and Hong Kong and through distribution channels. MTS shares are traded on the NASDAQ Capital Market (symbol MTSL). For more information please visit the MTS web site: http://www.mtsint.com.

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission.

Company Contact:

Alon Mualem
CFO
Tel: +972-9-7777-540
Email: alon.mualem@mtsint.com

(PTBI) Closes $10 Million Financing

Proceeds to Support Clinical Development of Gene & Cell Therapy Programs in Inherited COPD and Sanfilippo Syndromes (MPS IIIA & MPS IIIB)

(MYOS) Initiates Clinical Study on Fortetropin(R) Dose Response

Quantifying Standard and Minimal Effective Dose Will Expand Formulation Opportunities for Fortetropin(R); Clinical Study Will Be Conducted by Jacob Wilson, Ph.D, CSCS*D, Professor of Health Sciences and Human Performance at the University of Tampa

(GRVY) to Effect a 1-for-8 Reverse ADS Split

SEOUL, South Korea, May 11, 2015  — Gravity Co., Ltd. (Nasdaq:GRVY) (“Gravity” or “Company”) announced that it will effect a ratio change of its American Depositary Shares (“ADSs”) previously approved by the Company’s Board of Directors at a meeting held on April 22, 2015. The company is changing the ratio of its ADS to common share from four ADSs to one common share (4:1) to one ADS to two common shares (1:2), effective as of the start of trading on Monday, May 11, 2015. The ratio change will have the same effect as a 1-for-8 reverse split of its ADSs.

As a result of this ratio change, the total number of ADSs outstanding will be decreased from 13,095,692 to 1,636,961 and there will be no change to its common shares. The reverse ADS split is intended to increase the market price per ADS to allow the Company to maintain the listing on The NASDAQ Capital Market. However, the Company can give no assurance that this event will result in meeting the minimum bid price requirement of The NASDAQ Capital Market.

Background

As previously disclosed in a Current Report on Form 6-K dated June 3, 2014, the Company was notified by NASDAQ, on May 28, 2014, that it no longer satisfied the minimum bid price requirement for continued listing set forth in Nasdaq Stock Market Rule 5450(a)(1), as the bid price of the Company’s ADS had closed for 30 consecutive business days below US$1.00 per ADS. In accordance with Nasdaq Stock Market Rule 5810(c)(3)(A), the Company was granted a grace period of 180 calendar days, or until November 24, 2014, to regain compliance. Subsequently, the Company disclosed in a Current Report on Form 6-K dated November 25, 2014, that it received a positive determination from the Listing Qualifications department of The NASDAQ Stock Market, granting approval of the Company’s request to transfer its listing to The NASDAQ Capital Market from The NASDAQ Global Market. As a result, the Company was granted its second grace period of 180 calendar days, or until May 26, 2015 to regain compliance with NASDAQ.

About GRAVITY Co., Ltd.

Based in Korea, Gravity is a developer and publisher of online and mobile games. Gravity’s principal product, Ragnarok Online™, is a popular online game in many markets, including Japan and Thailand, and is currently commercially offered in 71 countries and markets. For more information about Gravity, please visit http://www.gravity.co.kr.

Forward-Looking Statements:

Certain statements in this press release may include, in addition to historical information, “forward-looking statements” within the meaning of the “safe-harbor” provisions of the U.S. Private Securities Litigation Reform Act 1995. Forward-looking statements can generally be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” “project,” or “continue” or the negative thereof or other similar words, although not all forward-looking statements contain these words. Investors should consider the information contained in our submissions and filings with the United States Securities and Exchange Commission (the “SEC”), including our annual report for the fiscal year ended December 31, 2014 on Form 20-F, together with such other documents that we may submit to or file with the SEC from time to time, on Form 6-K. The forward-looking statements speak only as of this press release and we assume no duty to update them to reflect new, changing or unanticipated events or circumstances.

CONTACT: Mr. Heung Gon Kim
         Chief Financial Officer
         Gravity Co., Ltd.
         Email: kheung@gravity.co.kr

         Ms. Ji Hee Kim
         IR Manager
         Gravity Co., Ltd.
         Email: ircommunication@gravity.co.kr
         Telephone: +82-2-2132-7800

(NETE) Announces New Sales Partner Financing and Marketing Initiatives

Empowering Sales Partner Business Growth Through Facilitation of up to $50 Million in Merchant Portfolio Financing, Expansion of Portfolio Acquisition Plan and New Sales Incentives

(INVT) SeeThruEquity Initiates Coverage on Inventergy Global, Price Target of $1.03

NEW YORK, NY / May 11, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Inventergy Global Inc. (NASDAQ: INVT) with a Price Target of $1.03.

The report is available here: INVT Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in Campbell, CA, Inventergy is an intellectual property (IP) investment and licensing company. Inventergy works with leading technology companies to help them attain greater monetization from their IP assets and let them focus on their core business operations. The IP monetization business has high margin potential for savvy patent owners, and Inventergy has deep expertise in the telecommunications industry, in particular, and is skilled at identifying, acquiring and licensing high quality patents.

“We see a large potential opportunity for Inventergy, and note that the company has amassed what appears to be a very impressive portfolio of over 760 patents in the telecom industry including seminal patents from a number of leading companies including Huawei, Nokia and Panasonic. We are also encouraged by the fact that Inventergy’s leadership team has held advanced technology and IP roles at a veritable Who’s Who of leading global technology companies, including: HP, Rambus, Nokia, Cisco, IBM, Apple, Marvel, Microsoft and Ericsson, among others,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $1.03 per share.”

Additional highlights from the report are as follows:

Massive opportunity in managing and monetizing IP assets

Protecting, defending and monetizing value from intellectual property is a critical component of operating in the global economy in the 21st century. Indeed, according to data from Ocean Tomo, 80% of the value of most companies is intellectual property, versus just 20% in 1975. This is especially true for companies operating in the technology and telecom industries, where change takes place rapidly and companies’ profit models are directly linked to their ability to generate revenue from their employees’ innovations either through product sales, services, or through the licensing of technology. At the same time, extracting value from IP assets has become an increasingly complex and time-consuming endeavor, and many companies lack the resources and/or capabilities to monetize the vast amount of their intellectual property used by other companies. Indeed, Gartner Research estimates that US firms annually waste “$1 trillion in underused IP assets by failing to extract full value.”

Compelling IP portfolio from Nokia, Huawei and Panasonic

Taken together, Inventergy spent approximately $10mn over two years to acquire its patent portfolio. The company amassed what appears to be an impressive collection of 760 patents from leading global technology players Huawei, Nokia, and Panasonic, which cover the use of fixed and mobile communications using Internet Protocol Multimedia Core Network Subsystems (IMS), enterprise Voice-over-Internet Protocol (VoIP), and 3G and 4G mobile broadband technology. We see the patent portfolio as well-conceived and believe there are significant synergies among the IP assets. Inventergy has identified 100 potential licensees for its three patent portfolios, and has disclosed that it is in various stages of discussion with 20 of these companies. The company completed its first licensing deal in February – a five year, $2mn deal with a mid-tier communications company, and is in litigation with telecom equipment suppliers Genband and Sonus Networks. Inventergy also announced a new mobile device licensing initiative that the company believes is applicable to over 1Bn new mobile handsets expected to be shipped this year, leveraging seminal patents acquired from Panasonic.

Strong management team experienced in creating value from IP

Led by its CEO Joe Beyers, Inventergy has an impressive senior management team and Board of Directors that has created over $10Bn in value from IP licensing transactions. The company’s management team and Board draw on experience from an impressive list of IP and technology companies, including Hewlett Packard (HP), Rambus, Nokia, Cisco, IBM, Marvel, Microsoft and Ericsson, among others. A seasoned technologist and inventor, Beyers had over 30 years of experience working at HP before becoming CEO of Inventergy. Beyers led strategy and planning at HP, where he also started seven software businesses, led HP’s $600mn / year internet business, and ran patent, standards, technology and brand licensing at the company.

Initiate coverage with a price target of $1.03

Our analysis indicates a fair value estimate of $1.03 per share, implying an upside of 238.7% from the recent price of $0.31. We view Inventergy as an intriguing speculative investment opportunity in the technology industry.

Please review important disclosures on our website at www.seethruequity.com.

About Inventergy Global Inc.

Inventergy Global, Inc. is a Silicon Valley-based intellectual property company dedicated to identifying, acquiring and licensing the patented technologies of market-significant technology leaders. Led by IP industry pioneer and veteran Joe Beyers, the Company leverages decades of corporate experience, market and technology expertise, and industry connections to assist Fortune 500 companies in leveraging the value of their innovations to achieve greater returns. For more information about Inventergy Global, visit http://www.inventergy.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com

(FUEL) Confirms Receipt of Unsolicited, Conditional Proposal

Advises Stockholders to Take No Action At This Time

Rocket Fuel (NASDAQ:FUEL), a leading programmatic marketing platform provider that uses artificial intelligence (AI) at Big Data scale to optimize marketing ROI for global agencies and enterprise marketers, today confirmed that it has received an unsolicited, conditional proposal from Gravity4 to acquire Rocket Fuel for $350 million in cash.

Consistent with its fiduciary duties, the Rocket Fuel Board of Directors will evaluate the proposal with the assistance of its financial and legal advisors. The Board advises stockholders to take no action at this time.

Rocket Fuel has established itself as a leader in programmatic marketing technology by using artificial intelligence to deliver superior campaign performance. Rocket Fuel is well positioned to expand its market leadership as programmatic marketing extends into every connected media channel and to the entire marketing cycle. Rocket Fuel is executing against its business imperatives to improve operating efficiency, deepen agency relationships and expand its enterprise relationships.

As announced on May 7, 2015, Rocket Fuel has delivered the following results:

• Quarterly revenues of $104.3 million for the first quarter of 2015, representing a 40% increase over the first quarter of 2014
• More than 80 new direct advertisers in Q1, resulting in 24% of revenue from direct advertisers and 76% through agencies
• Increased adoption of DMP and DSP self-service platforms by direct advertisers and the trading desks of two of the six major agency holding companies
• Q1 adjusted EBITDA results significantly better than guidance, reflecting initial results of efficiency initiatives and progress towards the goal of positive non-GAAP adjusted EBITDA for the full year

About Rocket Fuel

Rocket Fuel combines the science of Artificial Intelligence with the scale of Big Data to improve the effectiveness of programmatic marketing. Customers trust Rocket Fuel’s Marketing That Learns® to achieve brand and direct-response objectives in diverse industries across North America, Latin America, Europe, and APAC. With the acquisition of marketing technology firm [x+1] in September of 2014, Rocket Fuel now offers a complete programmatic marketing platform for the world’s most innovative, always-on marketers. The platform includes data management, programmatic media-buying, site optimization, and predictive analytics capabilities that extend across a marketer’s paid and owned channels, and personalize every customer interaction. Rocket Fuel operates in more than 20 offices worldwide and trades on the NASDAQ Global Select Market under the ticker symbol “FUEL.” For more information, please visit http://www.rocketfuel.com or call 1-888-717-8873.

Rocket Fuel, the Rocket Fuel logo, Advertising That Learns and Marketing That Learns are trademarks or registered trademarks of Rocket Fuel Inc. in the United States and other countries.

Investor Relations Contact:
The Blueshirt Group
Whitney Kukulka, 415-489-2187
ir@rocketfuel.com
or
Media Contact:
Kenya Hayes, 650-481-6178
pr@rocketfuel.com

(NDRM) Announces Lifting of FDA Clinical Hold on ND0612

ND0612H and ND0612L U.S. Clinical Development Cleared to Proceed

REHOVOT, Israel, May 8, 2015  — NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, the company’s primary product candidates, that are based on proprietary, subcutaneously-delivered Levodopa/Carbidopa (LD/CD) liquid formulation, for the treatment of Parkinson’s disease. The hold was lifted after the FDA reviewed additional information related to the product candidates’ delivery devices. U.S. clinical development of these product candidates is therefore cleared to proceed in the second half of 2015.

“Having lifted the clinical hold in the first half of 2015 means that our U.S. clinical development program of ND0612H and ND0612L is proceeding on track,” said Oded Lieberman, PhD, CEO of NeuroDerm. “Parkinson’s patients have been hoping for a less invasive, non-surgical alternative that can deliver levodopa continuously. We remain committed to the execution of our plan to bring these product candidates to the market as soon as possible, and to make a significant impact on the lives of Parkinson’s patients.”

In June 2014, the FDA placed a hold on the U.S. clinical development of ND0612H and ND0612L, requesting additional information on the accuracy, safety, and compatibility of the devices used to deliver the drug. The company completed the required compatibility study and submitted the requested additional information to the FDA. Following the FDA’s decision to lift the clinical hold, the company’s U.S. clinical development program is now cleared to proceed, with several studies anticipated to commence in the second half of 2015.

About Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient’s motor and non-motor functions. Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient’s quality of life. As the disease progresses, these symptoms become more severe, resulting in debilitating periods of decreased motor and non-motor functions, also referred to as “off” time. In addition, mainly as a result of excessive/intermittent oral doses of levodopa aimed at treating the “off” time, some patients experience involuntary movements, or dyskinesia. The “off” time and dyskinesia affect the majority of Parkinson’s disease patients and interfere with day-to-day functions, causing patients to become severely disabled. Continuous administration of levodopa has been shown to effectively treat motor fluctuations in Parkinson’s disease patients, however, a convenient route of continuous administration has not been introduced to date.

About Levodopa

Oral administration of LD/CD is regarded as the “gold standard” treatment for patients suffering from Parkinson’s disease. Levodopa crosses into the brain and converts into dopamine to complement the reduced brain-dopamine levels. Virtually all patients diagnosed with Parkinson’s disease will require levodopa at some point over the course of their treatment for the disease, and 70% to 80% of patients receive the drug at any given point in time. However, levodopa is limited by its short half-life. Approximately three to four hours after a single dose, almost none of the drug remains in the plasma and patients are required to take multiple LD/CD doses daily. This results in sharp fluctuations in levodopa levels which are associated with erratic “off” and “on” periods experienced by many patients. In addition, levodopa suffers from low absorption when administered orally, with only about 30% of the levodopa entering the blood stream. Continuous levodopa administration can overcome this limitation, but steady levodopa delivery can currently only be achieved after undergoing an invasive surgical procedure whereby a tube is permanently implanted into the duodenum, the upper part of the small intestine.

ND0612H, ND0612L

ND0612H and ND0612L are designed to significantly reduce motor complications in Parkinson’s disease patients through continuous, subcutaneous delivery of LD/CD. Recently completed phase II trials demonstrated that ND0612L maintained steady, therapeutic levodopa plasma concentrations that were associated with major improvements in several clinical parameters including “off time” reductions when added to optimized oral standard of care. ND0612H, intended for severe Parkinson’s disease patients, was shown to reach even higher levodopa steady plasma levels, indicating that it may provide an effective therapy alternative to current treatments requiring surgery such as deep brain stimulation and DuoDopa/Duopa®.

About NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. In Parkinson’s disease, the company has four product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. The company has developed a line of LD/CD product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD line of product candidates includes: ND0612L and ND0612H, delivered subcutaneously, for moderate and for advanced Parkinson’s disease patients, respectively, and ND0680 for a subset of severe Parkinson’s disease patients whose symptoms have advanced to a highly advanced stage, requiring even higher doses of LD/CD. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2014 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

CONTACT: NeuroDerm Contact:
         Oded S. Lieberman, PhD, MBA, CEO
         oded@neuroderm.com
         Tel.: +972-8-946 2729
         Cell: +1-617-517 6077

         U.S. Investor/Media  Contact:
         David Carey
         Lazar Partners Ltd.
         dcarey@lazarpartners.com
         +212-867-1762

(VNRX) Accelerates Nucleosomics® Clinical Trial with University Hospital Bonn

Study expanded to evaluate VolitionRx’s proprietary Nucleosomics® platform in 4,200 patient samples across 27 of the most prevalent cancers Sample collection nearly complete, accelerated analysis to begin in early Q3 2015 with dedication of two automated robots

NAMUR, Belgium, May 8, 2015  — VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics^® platform at University Hospital Bonn in Germany. VolitionRx has dedicated two of its recently-procured Tecan EVO200 automated laboratory robots to the study, with sample analysis to begin early in the third quarter of 2015. In addition, VolitionRx and study lead Prof. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn in Germany have increased the sample size and breadth of cancer types being tested.

The study initially included 4,000 patient blood samples across 20 of the most prevalent cancer types, and has now been expanded to include approximately 4,200-patient blood samples across 27 of the most prevalent cancers, including: two types of respiratory cancer, seven types of gastrointestinal cancer, four gynecological cancers, four urinary cancers, four types of hematological cancer, plus melanoma, sarcoma and cancers of the thyroid and brain; as well as control patients with 24 other conditions and healthy individuals. In total, the cancer types being analyzed represent over 95% of the incidence of cancer.

Dr. Jake Micallef, VolitionRx’s Chief Scientific Officer, said, “This trial is an incredibly important one, which we hope will show the breadth of our Nucleosomics^® technology. The trial is not only essentially 27 pilot studies in the most common cancers, but we are also looking for differences between cancers, and between cancers and other diseases, to discover if a panel of assays can detect several cancers from the same blood draw. We are grateful to Prof. Holdenrieder for his commitment to this ongoing multi-year trial, demonstrated by the increase of sample size and broadening of cancer types being evaluated in the trial – both of which we hope will enable us to more clearly demonstrate accuracy rates of our NuQ^® test in these patient populations.”

Cameron Reynolds, Chief Executive Officer of VolitionRx, commented, “We are very excited that with the addition of two fully-operational automated robot systems, analysis of the full 4,200 sample collection is on track to begin early in the third quarter of 2015. We expect to analyze the samples with up to 10-15 NuQ^® assays by the first quarter of 2016. The aim of the trial is both to evaluate a large number of cancers and to look for a panel of assays that can diagnose multiple cancers for potential new products beyond the current four cancers we are evaluating.”

Prof. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn in Germany, who is leading the study, added, “Collectively, cancer is one of the foremost causes of mortality around the world and there remains a significant global need for improved early cancer detection. An accurate and non-invasive test using only a drop of blood that could detect a range of cancers would provide physicians and patients an opportunity to treat the disease early on, before the cancer metastasizes, providing greater chances of survival. Collection and analysis of samples has been, and will continue to be, carried out in my laboratory with VolitionRx providing the assays for analysis. I am very much looking forward to seeing the results from this study.”

The NuQ^® tests utilize the Company’s proprietary Nucleosomics^® technology platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood.

Clinical trials assessing the effectiveness of VolitionRx’s assays include:

Colorectal cancer:

• A 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark)
• A 14,000 patient prospective screening study (Hvidovre Hospital, University of Copenhagen, Denmark)
• A 250 patient prospective study (CHU-UCL Mont Godinne Hospital, Belgium)

Pre-cancerous colorectal adenomas:

• A 800 patient prospective study (Hvidovre Hospital, University of Copenhagen, Denmark)

27 most prevalent cancers

• A 4,200 patient prospective study that involves patients with the 27 most prevalent cancers (University Hospital, Bonn, Germany)

Lung cancer:

• A 600 patient prospective confirmatory study (University Hospital, Bonn, Germany)

Prostate cancer:

• A retrospective study to establish the efficacy of VolitionRx’s NuQ^® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form (MD Anderson Cancer Center, Texas)
• A 120 patient prospective feasibility study (ImmuneHealth, Belgium)

Ovarian cancer:

• A 40 patient prospective feasibility study (Singapore General Hospital, Singapore)

Endometriosis

• A prospective study to assess VolitionRx’s NuQ^® tests for the diagnosis of endometriosis (the University of Oxford, United Kingdom)

About VolitionRx

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx’s website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.

Media Contacts

Charlotte Reynolds, VolitionRx
Charlotte.Reynolds@volitionrx.com
Telephone: +44 (0) 795 217 7498

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests” and similar expressions identify forward-looking statements.  These forward-looking statements relate to the effectiveness of the Company’s bodily-fluid-based diagnostic tests as well as the Company’s ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company’s development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

(ICLD) is Awarded Cloud Solutions Contract With Major Auto Parts Distributor

SHREWSBURY, N.J., May 8, 2015  — InterCloud Systems, Inc. ( the “Company or “InterCloud” ) (Nasdaq:ICLD) a single-source provider of end-to-end information technology (IT) and next-generation network solutions including Software Defined Networking (SDN) and Network Functions Virtualization (NFV) to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services, announced today that our cloud team has been engaged by a large east coast auto parts distributor and wholesaler to design, migrate and implement a cloud solution to house a web services infrastructure, centralizing point of sale (POS), and inventory data across all store locations. InterCloud’s solution will include development, quality assurance, production and disaster recovery environments, and will employ industry leading storage and delivery technologies.

CEO Mark Munro stated, “We continue to see a steady flow of new cloud customers and are building recurring revenue streams in the small and medium size business (SMB) market segment. SMB customers are finding the cloud to be a secure and economical means to completely outsource their IT infrastructure and applications. Our solutions allow these customers to eliminate in house IT staff as we take full responsibility for their IT needs. This customer is an excellent example of how a business can have access to the latest technology, save money, speed up time to market, and get enterprise grade IT solutions at a competitive cost. InterCloud is well positioned to manage our customers technology demands.”

About InterCloud Systems, Inc.

InterCloud Systems, Inc. is a single-source provider of end-to-end information technology (IT) and next-generation network solutions including Software Defined Networking (SDN) and Network Function Virtualization (NFV) to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services. InterCloud offers cloud and managed services, professional consulting and staffing services, and infrastructure and applications to assist its customers in meeting their changing technology demands. InterCloud’s cloud solutions offer enterprise and service-provider customers the opportunity to adopt an operational expense model by outsourcing to InterCloud rather than the capital expense model that has dominated in recent decades in IT infrastructure management. Additional information regarding InterCloud may be found on InterCloud’s website at www.intercloudsys.com.

Forward-looking statements:

The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.

CONTACT: Investor Relations
         InterCloud Systems, Inc.
         561-988-1988

(ISR) Thomas Jefferson University Launches Major Head and Neck Cancer Study

Successful Cesium-131 Cancer Treatment Results, as Reported by Other Institutions, Are Driving New Institutions to Offer Cesium-131 Therapy

(QADB) to Present and Conduct One-on-One Investor Meetings

QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB), a leading provider of enterprise business software and services for global manufacturers, today announced that Daniel Lender, Executive Vice President and Chief Financial Officer, will present an overview of the company at the 16^th Annual B. Riley Investor Conference on Wednesday, May 13, 2015 at 9:30 a.m. PT at the Loews Hollywood Hotel in Los Angeles. The company also will conduct one-on-one meetings with investors throughout the day.

A live webcast of the presentation will be available on the company’s website at www.qad.com. An archive will be available on the site for 90 days following the live presentation.

About QAD – The Effective Enterprise

QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB) is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 35 years, QAD has provided global manufacturing companies with QAD Enterprise Applications, an enterprise resource planning (ERP) system that supports operational requirements; including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD Enterprise Applications is offered in flexible deployment models as on-premise software, in the cloud with QAD Cloud ERP or in a blended environment. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.

For more information about QAD, call +1 805-566-6000, visit www.qad.com.

“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.

Note to Investors: This press release contains certain forward-looking statements made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the Company’s business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company’s current expectations. Words such as “expects,” “believes,” “anticipates,” “could,” “will likely result,” “estimates,” “intends,” “may,” “projects,” “should,” “would,” “might,” “plan” and variations of these words and similar expressions are intended to identify these forward-looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: risks associated with our cloud service offerings, such as defects and disruptions in our services, our ability to properly manage our cloud service offerings, our reliance on third-party hosting and other service providers, and our exposure to liability and loss from security breaches; demand for the company’s products, including cloud service, licenses, services and maintenance; pressure to make concessions on our pricing and changes in our pricing models; protection of our intellectual property; dependence on third-party suppliers and other third-party relationships, such as sales, services and marketing channels; changes in our revenue, earnings, operating expenses and margins; the reliability of our financial forecasts and estimates of the costs and benefits of transactions; the ability to leverage changes in technology; defects in our software products and services; third party opinions about the company; competition in our industry; the ability to recruit and retain key personnel; delays in sales; timely and effective integration of newly acquired businesses; economic conditions in our vertical markets and worldwide; exchange rate fluctuations; and the global political environment. For a more detailed description of the risk factors associated with the company and factors that may affect our forward-looking statements, please refer to the company’s latest Annual Report on Form 10-K and, in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.

(ZIOP) Appoints Laurence J. N. Cooper, M.D., Ph.D., Chief Executive Officer

BOSTON, May 7, 2015  — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the appointment of Laurence J. N. Cooper, M.D., Ph.D., to the role of Chief Executive Officer, effective immediately. Dr. Cooper brings extensive experience in pioneering the development of adoptive cellular therapies in the field of oncology and translating immunology into clinical practice. He succeeds Jonathan Lewis, M.D., Ph.D., who will remain a member of the Company’s Board of Directors.

“The addition of Dr. Cooper further enhances the progress of ZIOPHARM in building a world-class suite of programs and technologies for advancing the leading, regulated immuno-oncology gene and adoptive CAR T, TCR and NK cell therapies,” said Sir Murray Brennan, M.D., Lead Director of ZIOPHARM. “We thank Jon Lewis for his lifelong commitment to science and clinical care and his contributions during his years of service as CEO of the Company. At this stage in ZIOPHARM’s evolution, Dr. Cooper’s appointment is a tremendous gain for the Company, given his expertise in immunotherapy and central role in the development and clinical translation of MD Anderson Cancer Center’s adoptive cell therapy programs.”

“By harnessing and enhancing the power of the immune system, adoptive cell therapy holds the promise of curing many cancers,” said Dr. Cooper. “Central to achieving this objective is our ability to solve the puzzle of linking together different proteins, receptors, cell types, gene switches and associated technologies to target a broad spectrum of malignancies. Together, I believe ZIOPHARM, Intrexon, MD Anderson and Merck Serono have the technologies, programs and know-how to lead this effort, and I look forward to driving our success in this new role.”

Dr. Cooper added: “ZIOPHARM has unique potential in the human application of immune cells. The synthetic biology of Intrexon is being combined with ZIOPHARM’s ability to deliver potent therapeutics. Together with our partners, we have a unique opportunity to bring new immune-based therapies into the war on cancer.”

Dr. Cooper joined The University of Texas MD Anderson Cancer Center in 2006, where his appointments include tenured professor, Pediatrics and Immunology; Section Chief, Cell Therapy, Children’s Cancer Hospital; and Associate Director, Center for Cancer Immunology Research. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.  Dr. Cooper has received numerous awards and honors and in addition to numerous other professional appointments, he has authored more than 140 journal articles, book chapters, and abstracts.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer. The Company’s synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation’s RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the progress, timing and results of preclinical and clinical trials involving the Company’s drug candidates, and the progress of the Company’s research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-IL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-IL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks

RheoSwitch Therapeutic System® (RTS^®) technology is a registered trademark of Intrexon Corporation.

CONTACT: David Pitts or Eliza Schleifstein
         Argot Partners
         212-600-1902
         david@argotpartners.com
         eliza@argotpartners.com

(GEVO) Renewable Alcohol-Based Jet Fuel Commercial Launch Partner Alaska Airlines

ENGLEWOOD, Colo., May 7, 2015  — Gevo, Inc. (Nasdaq:GEVO) announced today that it has signed a strategic alliance agreement with Alaska Airlines to purchase Gevo’s renewable jet fuel and fly the first-ever commercial flight on alcohol-to-jet fuel (ATJ).

The demonstration flight is expected to occur after Gevo receives ASTM International certification for its fuel, sometime in mid to late 2015. Gevo has been working through the rigorous ASTM process for six years, which includes extensive engine testing and data analysis by all of the major original equipment manufacturers to establish the specification for this drop in fuel. Once approved, this fuel can be seamlessly integrated into the existing distribution infrastructure and onto commercial aircraft.

“Developing a domestic, competitively priced, sustainable supply of biofuels is fundamental to the future of American aviation,” said Joe Sprague, senior vice president of external relations at Alaska Airlines. “The cost of fossil-based jet fuel is one of the largest expenses for airlines. This investment in Gevo’s ATJ will help reduce our exposure to high fuel prices, minimize our carbon footprint and demonstrate growing demand for fuel alternatives.”

“A sustainable biofuels industry would help insulate airlines from fuel price spikes, enabling them to offer economical air travel while remaining profitable, while helping meet their environmental goals, and spur economic growth within and outside of aviation,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer. “We greatly appreciate Alaska Airlines as a commercial partner as we move towards commercialization.”

Gevo’s patented ATJ is a clean burning, homegrown, drop-in jet fuel, which has the potential to deliver aviation biofuels at scale and at competitive cost.

Alaska Airlines was the first U.S. airline to fly multiple commercial passenger flights using a biofuel from used cooking oil. The carrier flew 75 flights between Seattle and Washington, D.C. and Seattle and Portland in November 2011. The airline has set a goal to using sustainable aviation biofuel at one or more of its airports by 2020.

About Gevo

Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize biobased alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water.

About Alaska Airlines

Alaska Airlines, a subsidiary of Alaska Air Group (NYSE:ALK), together with its partner regional airlines, serves more than 100 cities through an expansive network across the United States, Canada and Mexico. For more news and information, visit the Alaska Airlines/Horizon Air Newsroom at www.alaskaair.com/newsroom.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that are not purely statements of historical fact, and can sometimes be identified by our use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive” and similar words. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2014, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Gevo.

CONTACT: Media & Investor Contact:
         Mike Willis
         Gevo, Inc.
         T: (720) 267-8636
         mwillis@gevo.com

(ENG) Reports First Quarter 2015 Results

HOUSTON, May 7, 2015  — ENGlobal (Nasdaq:ENG), a leading provider of engineering and automation services, today announced its financial results for the first quarter ended March 28, 2015.

HIGHLIGHTS OF CONTINUING OPERATIONS:

• Revenue of $23.1 million
• Gross profit margin of 17.8%
• Net income of $0.02 per diluted share

Revenues in the first quarter of 2015 were $23.1 million, a decrease of 14.1% from $26.9 million in the prior year period. ENGlobal reported net income of $0.6 million, or $0.02 per diluted share, for the quarter ended March 28, 2015, compared to net income of $1.8 million, or $0.07 per diluted share, for the quarter ended March 29, 2014. During the quarter ended March 28, 2015, the Company incurred non-cash expenses for depreciation, amortization and stock compensation of $0.6 million as compared to $0.7 million for the same period in 2014.

Management’s Assessment

Mark Hess, ENGlobal’s Chief Financial Officer, said: “The recent downturn in energy commodity prices has negatively impacted our business thus far in 2015 by contributing to cancellations of upstream related orders at the beginning of the first quarter. We expect continued softness in our business until overall project activity in the energy sector improves.”

Mr. Hess continued: “We ended the first quarter with a healthy cash balance and working capital of $24.4 million, and have no borrowings under our current credit facility. In addition, notes receivable totaling $5.1 million were collected after the end of the quarter, contributing significantly to our cash position. While there is always room for improvement, I believe we are in a strong financial position and poised for future growth.”

“We have pared the Company down to a smaller, more focused operation and reduced the risk profile of the projects we are undertaking, in addition to controlling overhead costs,” said William Coskey, P.E., Chairman and Chief Executive Officer of ENGlobal. “These and other actions have allowed the Company to remain profitable, with positive cash flow during this downturn.”

The following table illustrates the composition of the Company’s revenue and profitability for its operations for the three months ended March 28, 2015 and March 29, 2014:

The following table presents certain balance sheet items as of March 28, 2015 and March 29, 2014:

The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 28, 2015 will be filed with the Securities and Exchange Commission today reflecting these results.

About ENGlobal

ENGlobal (Nasdaq:ENG) is a provider of engineering and automation services primarily to the energy sector throughout the United States and internationally. ENGlobal operates through two business segments: Automation and Engineering. ENGlobal’s Automation segment provides services related to the design, fabrication and implementation of distributed control, instrumentation and process analytical systems. The Engineering segment provides consulting services for the development, management and execution of projects requiring professional engineering, construction management, and related support services. Within the Engineering segment, ENGlobal’s Government Services group provides engineering, design, installation and operation and maintenance of various government, public sector and international facilities, and specializes in the turnkey installation and maintenance of automation and instrumentation systems for the U.S. Defense industry worldwide. Further information about the Company and its businesses is available at www.ENGlobal.com.

Safe Harbor for Forward-Looking Statements

The statements above regarding the Company’s expectations regarding its operations and certain other matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties including, but not limited to: (1) the effect of economic downturns and the volatility of oil and natural gas prices and significantly depressed oil prices since the end of 2014; (2) our ability to execute to our internal performance plans such as our post-divestiture outlook, productivity improvement and cost containment initiatives; (3) our ability to attract and retain key professional personnel; (4) our ability to retain existing customers and attract new customers; (5) our ability to realize revenue projected in our backlog and our ability to collect accounts receivable and process accounts payable in a timely manner; (6) our ability to identify, consummate and integrate potential acquisitions; (7) our reliance on third-party subcontractors and equipment manufacturers; (8) our ability to sustain profitability and positive cash flow from operations; (9) our ability to comply with the terms of our new credit facility; (10) operational and political risks in Russia and Kazakhstan along the Caspian Sea; (11) the effect of changes in laws and regulations with which the Company must comply and the associated costs of compliance with such laws and regulations; and (12) the effect of changes in accounting policies and practices as may be adopted by regulatory agencies. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in ENGlobal’s filings with the Securities and Exchange Commission. In addition, reference is hereby made to cautionary statements set forth in the Company’s most recent reports on Form 10-K and 10-Q, and other SEC filings.

Click here to join our email list: http://www.b2i.us/irpass.asp?BzID=702&to=ea&s=0.

CONTACT: Mark A. Hess
         (281) 878-1040
         ir@ENGlobal.com